MedTrace Logo

A Pilot Randomized Controlled Trial of Intravenous N-acetyl Cysteine in STEMI

NCT04023266 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2022-10-06

No results posted yet for this study

Summary

The PANACEA trial is an investigator-initiated prospective, single-center, two-arm, non-blinded pilot randomized controlled trial of high-dose IV N-Acetylcysteine therapy used as an adjunct to pharmaco-invasive reperfusion in patients presenting early after a large STEMI.

Conditions

  • STEMI

Interventions

DRUG

Intravenous N-Acetylcysteine

Intravenous N-acetyl cysteine bolus and infusion as described in the experimental arm.

Sponsors & Collaborators

  • University of Alberta

    lead OTHER

Principal Investigators

  • Michelle Graham, MD. FRCPC · University of Alberta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-20
Primary Completion
2020-11-15
Completion
2022-01-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04023266 on ClinicalTrials.gov